StemoniX
Pre-plated, human iPSC-derived microOrgans for toxicology and drug discovery research
Founded 2014
Maple Grove, United States
1 employees
Convertible Note
Total: $33.21M
Biotechnology, Health Care
Maple Grove, United States
1 employees
Convertible Note
Total: $33.21M
Biotechnology, Health Care
General Information
Company Name
StemoniX
Founded Year
2014
Location
Maple Grove, United States
Maple Grove, United States
Employees
1
Industries
Biotechnology, Health Care
Funding Stage
Convertible Note
BounceWatch is an independent company data service, not affiliated with StemoniX. To contact StemoniX, visit stemonix.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does StemoniX compare?
A PDF of StemoniX and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting StemoniX soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
About StemoniX
Business keywords: Stem Cell Technologies, Drug Discovery, Personalized Medicine, iPS Cells, Cardiomyocytes, Neurons, Astrocytes, High Throughput Screening, In Vitro Assay Development, Disease Modeling, Hazard Identification, Cell-based Assays, Toxicology Research, Regenerative Medicine
Funding Rounds & Investors (11)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Convertible Note | Undisclosed | 1 |
|
25 Aug 2020 |
| Venture Round | $100.00K | 1 |
|
15 May 2020 |
| Venture Round | $2.07M | - |
|
04 Oct 2019 |
| Series B | $14.40M | 5 |
|
28 Feb 2019 |
| Venture Round | $1.43M | - |
|
22 Aug 2018 |
| Venture Round | $4.93M | - |
|
04 Jun 2018 |
| Debt Financing | $305.00K | - |
|
20 Dec 2017 |
| Debt Financing | $1.48M | - |
|
24 Oct 2017 |
| Series A | $6.00M | 1 |
|
01 Feb 2017 |
| Seed Round | $2.50M | 5 |
|
03 Oct 2016 |
StemoniX Alternatives & Competitors
View All Alternatives
StemoniX vs
Altis Biosystems
United States
Capturing the Complexity of the Human Gut
Series A
28 employees
Biotechnology, Health Care
StemoniX vs
InvivoSciences® Inc.
United States
Discovery with Human touch
Non Equity Assistance
4 employees
Biotechnology, Health Care
StemoniX vs
MIMETAS
The Netherlands
Human Tissue Models for Better Therapies
Grant
93 employees
Biotechnology, Health Care
pixlbio
FAQ About StemoniX
Pre-plated, human iPSC-derived microOrgans for toxicology and drug discovery research
StemoniX was founded in 2014.
StemoniX is headquartered in Maple Grove, United States.
StemoniX operates in Biotechnology and Health Care. Its work centres on Stem Cell Technologies, Drug Discovery, Personalized Medicine and iPS Cells.
StemoniX has approximately 1 employees.
StemoniX has completed 11 funding rounds, raising a total of $33.21M. The latest funding stage is Convertible Note.
Top alternatives and competitors to StemoniX include Altis Biosystems, InvivoSciences® Inc., MIMETAS, Design Pharmaceuticals Inc., BellBrook Labs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
StemoniX and Altis Biosystems are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for StemoniX, https://bouncewatch.com/company/stemonix, updated 10 October 2024. When citing, please name BounceWatch and link this page.
